Please ensure Javascript is enabled for purposes of website accessibility
Taylor Carmichael

Taylor Carmichael


Taylor Carmichael is a former attorney and filmmaker. He's the author of a line of murder mysteries, including Whodidit in the Supreme Court? and Whodidit With a Senator? The majority of what he knows about stocks he learned right here at the Motley Fool.

Recent articles


Amarin vs. the Generics: Who Will Win?

After Amarin lost its patent rights in the U.S., the stock crashed overnight. Investors might want to stay optimistic.

GettyImages-1159049959 (1)

These 2 Under-the-Radar Stocks Are Great Buys Right Now

Freshpet and Afterpay have been stomping the market for years.


5 Under-the-Radar Tickers That Will Stomp the Market in 2021

Investors are hyper-focused on COVID-19 right now, but once vaccines for the virus have been approved, other healthcare stocks will start to zoom forward.


2 Dirt Cheap Robinhood Stocks That Could Skyrocket

When we fully recover from the coronavirus pandemic, airline and cruise ship stocks will zoom higher. That makes United Airlines and Royal Caribbean good candidates to double in a year or two.


2 Top Medical Device Stocks to Buy in November

There's good reason to think these young stocks have bright futures ahead.


Vaxart Reports More Positive Data From Animal Testing of Its Coronavirus Vaccine Candidate

The tiny biotech's COVID-19 vaccine has generated excitement because it's a pill instead of a shot, which gives it a number of important advantages.


2 Stocks to Ride the Crypto Wave

These two well-known companies will profit mightily from the rise of cryptocurrencies.


Novavax to Provide 40 Million Doses of Its COVID-19 Vaccine Candidate to Australia

Australia joins a growing list of countries that have locked in orders for NVX-CoV2373.


GW Pharmaceuticals Initiates Phase 3 Trial for Multiple Sclerosis Drug

The cannabinoid prescription drug Sativex has already been approved in numerous countries for reducing spasticity caused by MS.


If You Invested $10,000 in Novavax During the Coronavirus Market Crash, This Is How Much Money You'd Have Now

The negativity got so bad in March, even the COVID-19 vaccine stocks were punished.


Why My Family Bought Shares of Royal Caribbean Now

A vaccine for the coronavirus is highly likely to be approved over the next few months. When that happens, the cruise ship industry should quickly recover.


Nano-X Imaging Signs Deal With Ambra Health

Ambra Health's cloud solution will make it easier for medical professionals around the world to access the X-ray images taken by the new Nano-X device.


EU Regulator Grants Label Expansion for GlaxoSmithKline's Ovarian Cancer Therapy

The European Commission has joined the Food and Drug Administration in accepting Zejula as a front-line therapy.


2 Stocks to Buy Prior to the Election

Regardless of who wins the race for the White House, Bilibili and Tencent should continue to rock over the next four years.


Why Is Everybody Talking About Nano-X Stock?

The company's new X-ray will be a lot cheaper than existing technology. If it works as advertised, the device might be a game changer.


2 Surefire Coronavirus Stocks to Buy Right Now

As we (hopefully) approach the finish line in the COVID-19 vaccine race, it's a wonderful time to buy shares of Novavax and Sanofi.


Why I Just Bought These 2 Under-the-Radar Stocks

These fast-growing medical device companies could outperform the S&P 500 over the next several years.


Kamada Will Supply COVID-19 Treatment to Israel

The biotech specializes in plasma-derived protein therapeutics.


Why I'm Buying Shares of Ontrak and Unity Software

These two virtual stocks have runways for massive growth over the next decade.


Sanofi and Translate Bio Have a COVID-19 Vaccine Candidate Ready for Clinical Trials

The market leader in flu vaccines is trailing in the race to find an effective coronavirus vaccine.